Catalog No.
DHG54901
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
MAdCAM-1, hMAdCAM-1, MADCAM1, Mucosal addressin cell adhesion molecule 1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q13477
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
PF-00547659, PF-547659, SHP647, CAS: 2098790-40-8
Clone ID
Ontamalimab
Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances, PMID: 31127023
Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1), in Patients With Ulcerative Colitis or Crohn's Disease, PMID: 32119128
Anti-MADCAM therapy for ulcerative colitis, PMID: 31709847
Anti-trafficking agents in the treatment of inflammatory bowel disease, PMID: 31567498
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study, PMID: 34427633
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II, PMID: 33599720
Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1, PMID: 29757363
Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease, PMID: 29767705
PF-00547659 for the treatment of Crohn's disease and ulcerative colitis, PMID: 29985060
Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBD, PMID: 30696342
Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases, PMID: 25110260
Towards therapeutic choices in ulcerative colitis, PMID: 28527707
Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): Insights into promising agents, PMID: 34449288
IBD: Phase II trial success for anti-MADCAM1 antibody, PMID: 28611481
Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers, PMID: 30901380
Normal intrathecal leukocyte cell number and composition do not decrease the incidence of post-lumbar puncture headache, PMID: 28778448
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial, PMID: 28527704
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study, PMID: 28982740
Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn's Disease, PMID: 28961803
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study, PMID: 28961770
Physiologically relevant binding affinity quantification of monoclonal antibody PF-00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlation, PMID: 27760281
Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension, PMID: 19398651
For research use only. Not for human or drug use.
